RT Journal Article
SR Electronic
T1 Surveillance and Stability of SARS-CoV-2 Wastewater Samples in Minnesota
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.14.23296666
DO 10.1101/2023.10.14.23296666
A1 Osborn, Mark J.
A1 Champeau, Shannon
A1 Meyer, Carolyn
A1 Hayden, Mason
A1 Landini, Laura
A1 Stark, Stacey
A1 Preeket, Stephanie
A1 Vetter, Sara
A1 Lynfield, Ruth
A1 Huff, Daniel
A1 Schacker, Timothy W.
A1 Doss, Charles R.
YR 2023
UL http://medrxiv.org/content/early/2023/10/15/2023.10.14.23296666.abstract
AB Wastewater-based epidemiology provides an approach for assessing the prevalence of pathogens such as COVID-19 in a sewer service area. In this study, SARS-CoV-2 RNA was measured serially in 44 wastewater treatment plants of varying service capacities comprising approximately 67% of the population of Minnesota, from September 2020 through December 2022. We employed linear regression models to establish a predictive relationship between the weekly SARS-CoV-2 RNA concentrations in wastewater and clinical case counts. Metrics were assessed under specified transformation and normalization methods which we confirmed by cross-validation averaged across the enrolled treatment plants. We report that the relationship between COVID-19 incidence and SARS-CoV-2 RNA in wastewater may be treatment plant-specific. Toward establishing guidelines for pathogen surveillance, we further studied storage and time-to-analysis for RNA wastewater data and observed large effects of storage temperature, indicating that collection methods may have an important effect on the utility and validity of wastewater data for infectious disease monitoring. Our findings are additive for any large-scale wastewater surveillance program.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded, in part, by a grant from 3M and the Minnesota Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors